VEGFR3 does not sustain retinal angiogenesis without VEGFR2
about
Vascularisation of the central nervous systemAn Intronic Flk1 Enhancer Directs Arterial-Specific Expression via RBPJ-Mediated Venous Repression.Lymphangiogenesis and Inflammation-Looking for the "Missing Pieces" of the Puzzle.The matricellular protein CCN1 controls retinal angiogenesis by targeting VEGF, Src homology 2 domain phosphatase-1 and Notch signaling.Alk1 and Alk5 inhibition by Nrp1 controls vascular sprouting downstream of Notch.Endothelial Ca 2+ oscillations reflect VEGFR signaling-regulated angiogenic capacity in vivo.Regulating the regulators of angiogenesis by CCN1 and taking it up a NotchCarbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis.Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies.VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature.Modulation of Endothelial Bone Morphogenetic Protein Receptor Type 2 Activity by Vascular Endothelial Growth Factor Receptor 3 in Pulmonary Arterial Hypertension.Vascular heterogeneity and specialization in development and disease.Intestinal lymphatic vasculature: structure, mechanisms and functions.High-resolution 3D analysis of mouse small-intestinal stroma.Asymmetric division coordinates collective cell migration in angiogenesis.Fluid shear stress regulates vascular remodeling via VEGFR-3 activation, although independently of its ligand, VEGF-C, in the uterus during pregnancyCell-matrix signals specify bone endothelial cells during developmental osteogenesis.Uncontrolled angiogenic precursor expansion causes coronary artery anomalies in mice lacking Pofut1.Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract.VEGF165-induced vascular permeability requires NRP1 for ABL-mediated SRC family kinase activation.The CUL3-SPOP-DAXX axis is a novel regulator of VEGFR2 expression in vascular endothelial cells.PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia.Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells.Dll4 and Notch signalling couples sprouting angiogenesis and artery formation.Quantification of STAT3 and VEGF expression for molecular diagnosis of lymph node metastasis in breast cancer.Lymphangiogenesis guidance by paracrine and pericellular factors.Vascular deficiency of Smad4 causes arteriovenous malformations: a mouse model of Hereditary Hemorrhagic Telangiectasia.Vegfr3-CreER (T2) mouse, a new genetic tool for targeting the lymphatic system.Molecular mechanism of inhibition of the abnormal proliferation of human umbilical vein endothelial cells by hydroxysafflor-yellow A.The endothelial adaptor molecule TSAd is required for VEGF-induced angiogenic sprouting through junctional c-Src activation.VEGF-C promotes the development of lymphatics in bone and bone loss.Heterogeneity in VEGFR3 levels drives lymphatic vessel hyperplasia through cell-autonomous and non-cell-autonomous mechanisms.Counterbalance: modulation of VEGF/VEGFR activities by TNFSF15Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility
P2860
Q26801786-FB475C82-7F05-4A80-A539-426DC8271E63Q27342049-7F51D8BA-2E32-4271-8F07-F14B6BCAD12BQ33361133-60D0CDC0-915B-4737-879A-8F415EA0358BQ35877484-B82F02FF-693A-439B-8C33-6F12AFA1FC88Q36018663-FECE868F-DFD3-4F71-8747-EB7B40EA17F7Q36483799-BD4923BE-5597-4BFA-822E-EEEE35479B81Q37321743-4EC9DCF9-355F-403D-84DB-2A1142057087Q37610682-0ECF283A-183A-41F3-9D58-4132D798D532Q38600792-6FCC5CE4-24A6-4744-B619-B26DE984AADFQ38681382-D3E3D184-9C54-4BC9-9478-2ABA08F47B51Q38868346-7B0EB2F2-693A-44FA-A0E3-E95F7A6E1B48Q39326100-66778B93-2B12-462E-826D-5738819C3893Q39401415-452BD594-F7A0-4FA2-BA12-FFF4136ED38EQ40563361-AEC0B233-F2A9-4358-B851-77D1D8ABFEE7Q41301518-DFD9FD16-9432-47DA-BC80-8EE3F3F24CA7Q41351932-10D26AC4-B1C1-4E11-ACF6-E70586BF4FE9Q41591466-1CE64930-52EC-44CF-BA76-304D2B257F32Q41701270-319ADE29-EB6F-439B-85AF-A1227C595CFAQ41970819-11768E61-E43C-4C5D-B4B1-CF6935B5E072Q42292864-4C7F4A80-DE43-49D3-B281-51C2D1402EDCQ42320699-2A9F11A6-A332-4E7E-B41D-7ED05374957EQ42357211-000BEB01-CFD3-4DEA-A6CA-23FC835690B6Q46130631-EA0DD7ED-240A-4450-96CE-F126EC590DA4Q46340126-0F52B04B-BF9E-4695-8EAE-4FEC264CA83DQ47179344-3997A493-456A-4782-9FAF-DC1F3CB2AA50Q47744569-EC51A5BE-7C6C-45A9-917E-19D0A6E715A9Q49826259-F54C712A-83B9-45FF-AE03-7E743338D1DBQ50526980-F0A557B6-9344-4F00-9C57-5E657B426B32Q51576933-8716EA52-F023-4097-9CDF-EF0D0A86B9D7Q51629900-FF5F357A-4CB6-4D40-BB92-4A63975CB723Q52605044-B6A5D90E-7E63-45C1-9B96-0E556825E657Q55023685-757577A7-FC80-4BCB-8118-02EF2D93F04DQ58791672-C8F90030-A6E2-4B29-943B-52BA107391DBQ59128909-B5C4910B-D3CE-4A1F-AA2C-CABD8098DE5B
P2860
VEGFR3 does not sustain retinal angiogenesis without VEGFR2
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
VEGFR3 does not sustain retinal angiogenesis without VEGFR2
@ast
VEGFR3 does not sustain retinal angiogenesis without VEGFR2
@en
type
label
VEGFR3 does not sustain retinal angiogenesis without VEGFR2
@ast
VEGFR3 does not sustain retinal angiogenesis without VEGFR2
@en
prefLabel
VEGFR3 does not sustain retinal angiogenesis without VEGFR2
@ast
VEGFR3 does not sustain retinal angiogenesis without VEGFR2
@en
P2093
P2860
P356
P1476
VEGFR3 does not sustain retinal angiogenesis without VEGFR2
@en
P2093
Georgia Zarkada
Krista Heinolainen
Taija Makinen
Yoshiaki Kubota
P2860
P304
P356
10.1073/PNAS.1423278112
P407
P50
P577
2015-01-05T00:00:00Z